|
Treatment (tx) characteristics of patients (pts) with locally advanced or metastatic urothelial cancer (mUC) receiving checkpoint inhibitor (CPI) monotherapy in a US clinical practice. |
|
|
Honoraria - Astellas Pharma; Astellas Scientific and Medical Affairs Inc; AstraZeneca; Genentech; Janssen; Sanofi |
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Genentech; Sanofi |
Research Funding - AstraZeneca; Bayer; Genentech; Seattle Genetics/Astellas |
Travel, Accommodations, Expenses - Sanofi |
|
|
|
Honoraria - Alaunus Global; Clinical Care Options; Leerink; Merck; MI Bioresearch; PRMA Consulting |
Consulting or Advisory Role - Alcimed; Celgene; Defined Health; Five Prime Therapeutics; Genentech; Gfk; Leerink; Leerink; Merck; PureTech; Putnam Associates |
Research Funding - Amgen (Inst); Merck |
Patents, Royalties, Other Intellectual Property - PD-1/PD-L1 (Inst); Pending patent (DFCI 2386.010) (Inst) |
Travel, Accommodations, Expenses - Clinical Care Options; Genentech; Merck; PRMA Consulting; PureTech |
|
|
|
Stock and Other Ownership Interests - Genentech |
|
|
Employment - Roche/Genentech |
Stock and Other Ownership Interests - Roche/Genentech |
Research Funding - Roche/Genentech |
|
|
|
Stock and Other Ownership Interests - Roche |
|
|
|
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |